Source: MarketScreener

Solace Therapeutics, Inc.: Solace Therapeutics : Announces that Urology of Virginia Enrolls First Patient in US Pivotal Clinical Trial, using New Office-Based Treatment for Female Stress Urinary Incontinence(SUI).

(marketscreener.com) Urology of Virginia, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure. This press release features multimedia. View the full release here:...https://www.marketscreener.com/news/latest/Solace-Therapeutics-Announces-that-Urology-of-Virginia-Enrolls-First-Patient-in-US-Pivotal-Clinica--31847973/?utm_medium=RSS&utm_content=20201123

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Bill Gruber's photo - President & CEO of Solace Therapeutics

President & CEO

Bill Gruber

CEO Approval Rating

87/100

Read more